Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform
5 affiliations
- 1Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University Assiut 71526 Egypt (0020)-01044353895
- 2Faculty of Pharmacy and Drug Research, Assiut National University New Assiut City Assiut 11511 Egypt
- 3Department of Chemistry, Faculty of Science, King Khalid University Abha 61413 Saudi Arabia
- 4Department of Pharmaceutical Chemistry, College of Pharmacy, Najran University Najran Saudi Arabia
- 5Institute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology Karlsruhe 76131 Germany
Abstract
The development of isoform-selective histone deacetylase (HDAC) inhibitors remains a promising frontier for targeted cancer therapy, offering a strategic opportunity to maximize therapeutic efficacy while minimizing the adverse side effects of pan-HDAC inhibition. In this study, we present a novel series of 4-iodo-3-nitrophenyl-capped hydrazide and hydroxamate compounds that were developed, and investigated for potential to function as effective and preferential HDAC-2 inhibitors. In vitro enzyme assays revealed that this new scaffold prefers the HDAC-2 isoform over HDAC-1, which differs significantly from the non-selective reference medication, Vorinostat (SAHA). Upon testing these compounds with the propidium iodide (PI) fluorescence assay across many human cancer cell lines, we observed a remarkable, tissue-specific sensitivity. The foremost derivatives (7a, 7c, and 7d) exhibited much greater efficacy in inhibiting the growth of B-cell acute lymphoblastic (SEM) cells, exhibiting IC50 values ranging from 3.18 to 4.17 µM, surpassing the reference drug Vorinostat, which presented an IC50 of 5.23 µM. Western blot analyses in SEM cells revealed that the lead compound 7a bound to its intracellular target, resulting in an approximately 59% reduction in total HDAC-2 protein levels. Flow cytometry revealed that a significant reduction in HDAC-2 led to cancer cells being arrested at the key G2/M phase of the cell cycle, with 46.22% of cells detained there compared to merely 7.21% in untreated controls. Subsequent analysis using Annexin V/PI labeling demonstrated that this cell cycle arrest results in a significant elevation of programmed cell death, increasing total apoptosis to 31.12%, while maintaining non-specific necrosis at a minimal 4.29%. Taken together, these findings indicate that the 4-iodo-3-nitrophenyl compounds are effective tools for the targeted treatment of leukemia, displaying preferential HDAC-2 inhibitory activity among the evaluated class I isoforms.
Related
- Novel Quinoxaline-Based Cyanocarbonimidodithioate Derivatives as Non-Hydroxamate Selective HDAC8 Inhibitors: Design, Synthesis, Biological Evaluation and Mechanistic Studies
- Investigating the effect of glucosamine conjugation on the inhibitory activity of 2,3-dihydro-1H-perimidine derivatives against protein tyrosine phosphatases
- A Dipeptide Module Substitution-Based Strategy for the Modification and Evaluation of ACE Inhibitory Peptides.
- Xanthine oxidase inhibitory evaluation of prenylated flavonoids from peanut (Arachis hypogaea L.) shells: in vitro and in silico molecular docking studies.
- Targeting FTSJ1 to Restore TP53 Function in Nonsense Mutation-Driven Cancer: Computational and Experimental Evaluation of 1,2,4-Triazole Derivatives
BibTeX
@article{ali2026design,
title = {{Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform}},
author = {Fatma Elzahraa Ali and Abdullah Yahya Abdullah Alzahrani and Bandar A. Alyami and Stefan Bräse and Anber F. Mohammed and Bahaa G. M. Youssif},
journal = {RSC advances},
year = {2026},
month = nov,
doi = {10.1039/d6ra08049a},
url = {https://europepmc.org/article/PMC/PMC13729014},
note = {CC BY},
}
RIS
TY - JOUR
TI - Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform
AU - Fatma Elzahraa Ali
AU - Abdullah Yahya Abdullah Alzahrani
AU - Bandar A. Alyami
AU - Stefan Bräse
AU - Anber F. Mohammed
AU - Bahaa G. M. Youssif
PY - 2026
DA - 2026/11/03
JO - RSC advances
DO - 10.1039/d6ra08049a
UR - https://europepmc.org/article/PMC/PMC13729014
AB - The development of isoform-selective histone deacetylase (HDAC) inhibitors remains a promising frontier for targeted cancer therapy, offering a strategic opportunity to maximize therapeutic efficacy while minimizing the adverse side effects of pan-HDAC inhibition. In this study, we present a novel series of 4-iodo-3-nitrophenyl-capped hydrazide and hydroxamate compounds that were developed, and investigated for potential to function as effective and preferential HDAC-2 inhibitors. In vitro enzyme assays revealed that this new scaffold prefers the HDAC-2 isoform over HDAC-1, which differs significantly from the non-selective reference medication, Vorinostat (SAHA). Upon testing these compounds with the propidium iodide (PI) fluorescence assay across many human cancer cell lines, we observed a remarkable, tissue-specific sensitivity. The foremost derivatives (7a, 7c, and 7d) exhibited much greater efficacy in inhibiting the growth of B-cell acute lymphoblastic (SEM) cells, exhibiting IC50 values ranging from 3.18 to 4.17 µM, surpassing the reference drug Vorinostat, which presented an IC50 of 5.23 µM. Western blot analyses in SEM cells revealed that the lead compound 7a bound to its intracellular target, resulting in an approximately 59% reduction in total HDAC-2 protein levels. Flow cytometry revealed that a significant reduction in HDAC-2 led to cancer cells being arrested at the key G2/M phase of the cell cycle, with 46.22% of cells detained there compared to merely 7.21% in untreated controls. Subsequent analysis using Annexin V/PI labeling demonstrated that this cell cycle arrest results in a significant elevation of programmed cell death, increasing total apoptosis to 31.12%, while maintaining non-specific necrosis at a minimal 4.29%. Taken together, these findings indicate that the 4-iodo-3-nitrophenyl compounds are effective tools for the targeted treatment of leukemia, displaying preferential HDAC-2 inhibitory activity among the evaluated class I isoforms.
SN - 2046-2069
ER -